Recent research from Canada indicates a dramatic increase in adult ADHD stimulant prescriptions, with numbers more than doubling since the onset of the COVID-19 pandemic. This trend is reflected not only in Canada but also in countries like the U.S., Australia, the U.K., and Finland. Many mental health professionals corroborate these findings, noting an uptick in patients seeking ADHD treatment at their clinics during this period.

The study analyzed prescription data spanning from January 2016 to June 2024, revealing a notable shift in the demographics of those receiving stimulant medications. Specifically, the proportion of females among new recipients rose from 48% prior to the pandemic to 59% during the pandemic. Additionally, adults aged 25 to 34 saw the largest increase in prescriptions, indicating a change in the age and gender profile of ADHD diagnoses among adults.

As awareness and understanding of ADHD evolve, the data also shows a decreasing time frame between a patient's initial ADHD-related healthcare visit and their first prescription. By June 2024, the rate of adults prescribed stimulants hit a monthly average of 10.4 per 1,000 adults. These findings have raised alarms among doctors who are questioning the implications of this surge in diagnoses and prescriptions, especially regarding the long-term effects of stimulant use among adults.